Brainsway (BWAY) to Release Quarterly Earnings on Wednesday

Brainsway (NASDAQ:BWAY) is expected to announce its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Brainsway to post earnings of $0.11 per share and revenue of $14.0180 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 8:30 AM ET.

Brainsway Stock Down 2.2%

BWAY stock opened at $12.34 on Monday. Brainsway has a twelve month low of $3.92 and a twelve month high of $13.31. The firm has a market cap of $483.97 million, a price-to-earnings ratio of 82.27 and a beta of 1.20. The business’s fifty day simple moving average is $11.75 and its two-hundred day simple moving average is $9.35.

Institutional Trading of Brainsway

A number of institutional investors have recently bought and sold shares of BWAY. Millennium Management LLC increased its stake in Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after purchasing an additional 16,354 shares in the last quarter. UBS Group AG raised its holdings in shares of Brainsway by 2,028.6% in the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after buying an additional 60,877 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Brainsway during the third quarter worth $107,000. Two Sigma Investments LP lifted its stake in shares of Brainsway by 25.2% during the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares during the period. Finally, ARK Investment Management LLC purchased a new stake in shares of Brainsway during the fourth quarter valued at $2,422,000. 30.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BWAY has been the topic of several research reports. HC Wainwright lifted their price objective on shares of Brainsway from $12.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings restated a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. Northland Securities set a $15.00 target price on Brainsway in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.